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Abstract
Background: Patients with metastatic breast cancer are frequently treated with anthracyclines and taxanes, which are
among the most active agents in this disease. Gemcitabine is an interesting candidate for a three-drug combination
because of its different mechanism of action and non-overlapping toxicity with respect to the other two drugs. We aimed
to evaluate the activity and toxicity of the GAT (gemcitabine, doxorubicin and paclitaxel) regimen, derived from
experimental preclinical studies, as first-line chemotherapy in patients with stage IIIB-IV breast cancer.
Methods: Patients with locally advanced or metastatic breast cancer and at least one bidimensionally measurable lesion
were included in the present study. Adequate bone marrow reserve, normal cardiac, hepatic and renal function, and an
ECOG performance status of 0 to 2 were required. Only prior adjuvant non anthracycline-based chemotherapy was
permitted. Treatment consisted of doxorubicin 50 mg/m2 on day 1, paclitaxel 160 mg/m2 on day 2 and gemcitabine 800
mg/m2 on day 6, repeated every 21–28 days.
Results: Thirty-three consecutive breast cancer patients were enrolled onto the trial (7 stage IIIB and 26 stage IV). All
patients were evaluable for toxicity and 29 were assessable for response. A total of 169 cycles were administered, with
a median of 6 cycles per patient (range 1–8 cycles). Complete and partial responses were observed in 6.9% and 48.3%
of patients, respectively, for an overall response rate of 55.2%. A response was reported in all metastatic sites, with a
median duration of 16.4 months. Median time to progression and overall survival were 10.2 and 36.4 months,
respectively. The most important toxicity was hematological, with grade III-IV neutropenia observed in 69% of patients,
sometimes requiring the use of granulocyte colony-stimulating factor (27%). Non hematological toxicity was rare and
mild. One patient died from sepsis during the first treatment cycle before the administration of gemcitabine.
Conclusion: The strong synergism among the three drugs found in the preclinical setting was confirmed in terms of
both clinical activity and hematological toxicity. Our results seem to indicate that the GAT regimen is effective in
anthracycline-naïve metastatic breast cancer and provides a feasible chemotherapeutic option in this clinical setting.
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Background
Breast cancer is the most common malignancy and the
leading cause of cancer mortality in European women.
Despite the advances made in treatment options, which
have led to a significant increase in survival and quality of
life, metastatic disease is still incurable.
Anthracyclines and taxanes are considered the most active
drugs for the treatment of metastatic breast cancer (MBC)
[1,2], and combination regimens of these agents com-
pared with standard anthracycline-containing chemother-
apy in phase III randomized trials [3-9] have shown a
higher activity (range of improvement 5–38%) of the
former. A significantly higher progression-free survival
has generally been observed, whereas only one trial
described an important improvement in overall survival
[3]. It has therefore been concluded that anthracycline-
naive MBC patients who are candidates for chemotherapy
should be treated with an anthracycline-containing regi-
men (possibly in combination with taxanes).
Gemcitabine has shown a high antitumor activity in the
treatment of MBC both as single agent and in association
with other cytotoxic drugs [10,11]. We hypothesized that
paclitaxel, doxorubicin and gemcitabine could be a poten-
tially good combination because of the non-overlapping
toxicity, the different mechanisms of action, and the pos-
sible lack of cross-resistance of the drugs. In a preclinical
study on in vitro breast cancer cell lines, we observed a syn-
ergistic interaction with the sequence doxorubicin → pacl-
itaxel → 48-h wash-out → gemcitabine [12,13]. On the
basis of these results, we then conducted a phase I dose-
finding clinical trial on patients with MBC to identify the
recommended doses of the drugs [14].
In the present phase II study we aimed to verify whether
the strong synergism found in the preclinical in vitro
model would be confirmed in clinical practice.
Methods
Eligibility criteria
Eligibility criteria were as follows: females with histologi-
cally and/or cytologically confirmed stage IIIB-IV breast
cancer; age between 18 and 70 years; Eastern Cooperative
Oncology Group (ECOG) Performance Status 0–2; life
expectancy > 12 weeks; adequate cardiac function (left
ventricular ejection fraction ≥ 50% by echocardiogram);
adequate hepatic and renal function: creatinine and total
bilirubin ≤ 1.5 × upper limit of normal, AST e ALT ≤ 3 ×
upper limit of normal (≤ 5 in patients with liver metas-
tases); adequate bone marrow reserve: absolute neu-
trophil count (ANC) ≥ 1.5 × 109/L, platelet count ≥ 100 ×
109/L, hemoglobin ≥ 9 g/dl. Patients were required to
have at least one lesion that was bidimensionally measur-
able according to WHO criteria, and the presence of only
bone metastases was allowed if they were osteolytic
lesions and had not previously been treated with radio-
therapy. Patients were enrolled irrespective of hormone
receptor or menopausal status and HER2/neu expression.
Exclusion criteria
Exclusion criteria were: active serious infections or severe
concomitant diseases (at the discretion of the investiga-
tor); known central nervous system tumors, including
metastatic brain disease; pregnancy or breast-feeding; pre-
vious or concurrent malignancy other than breast cancer,
except for non melanoma skin cancer or curatively treated
carcinoma in situ of the uterine cervix. Prior chemotherapy
was limited to one adjuvant non anthracycline-based
treatment, and was not permitted for metastatic disease.
Previous hormone therapy in an adjuvant setting or for
metastatic disease was allowed, provided the patient had
progressive disease at study entry. No other anticancer
drugs, and only bisphosphonates and palliative radiother-
apy of non target lesions were allowed.
All patients gave written informed consent to receive treat-
ment and the study was examined and approved by the
Ethics committee of the Local Health and Social Services
of each participating center, in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki.
Treatment plan
The GAT regimen, as defined in the phase I trial, consisted
of doxorubicin (A) 50 mg/m2 on day 1, paclitaxel (T)160
mg/m2 on day 2 after 16–24 hours, and gemcitabine (G)
800 mg/m2 on day 6. Cycles were repeated every 21–28
days. Patients were premedicated with methylpred-
nisolone 125 mg i.m. or orally 12 and 6 hours before pacl-
itaxel treatment. Chlorphenamine 10 mg and cimetidine
300 mg were administered intravenously 30 and 15 min-
utes before paclitaxel, respectively, and antiemetics and
colony-stimulating growth factors were administered at
the discretion of the investigating physician.
Treatment was given for a maximum of eight cycles and
was discontinued in cases of unacceptable toxicity, disease
progression, patient refusal, or when, in the judgement of
the investigator, a different treatment would be more
appropriate for the patient's overall clinical status. In the
event of cardiotoxicity or if deemed clinically appropriate,
the 7th and 8th cycles could be administered without dox-
orubicin.
Dose reductions were made in the presence of hematolog-
ical toxicity (ANC < 0.5 × 109/L and/or platelet count < 50
× 109/L lasting more than 7 days) or grade 3 non hemato-
logical toxicity (other than alopecia and nausea/vomit-
ing). Patients were taken off study if grade IV febrileBMC Cancer 2006, 6:76 http://www.biomedcentral.com/1471-2407/6/76
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neutropenia, thrombocytopenia with severe bleeding, or
any grade IV non hematological toxicity occurred.
Statistical plan
The primary endpoint of the study was to assess the over-
all response rate in patients treated with the GAT regimen.
Secondary endpoints were toxicity, duration of response,
time to progression (TTP) and overall survival (OS).
The trial was conducted using a Simon optimal one-stage
design to test the null hypothesis that the response rate
was ≤ 30% versus the alternative that it was at least 50%.
Thirty-six assessable patients were to be enrolled. If 16 or
more objective responses were observed, the regimen
would be considered worthy of additional evaluation in
this disease. This design yields at least an 80% probability
of a positive result if the true response rate is at least 50%,
and at least a 95% probability of a negative result if the
true response rate is at most 30%.
Efficacy analysis was performed on both intention-to-treat
and assessable patient populations. Objective response
rates were calculated with 95% confidence intervals. Tox-
icity analysis was performed on the safety population, i.e.
patients having received at least one dose of study treat-
ment. Kaplan-Meyer estimations were used to evaluate
response duration, TTP and OS.
Evaluation of activity and toxicity
Screening evaluation included full medical history, physi-
cal and neurological examinations, tumor measurements
(by chest x-ray, abdominal ultrasound, or CT scan and
bone scan), cardiac function examination (ECG, echocar-
diogram), hematological and biochemistry analyses
including tumor markers CEA and CA15.3, and other
evaluations if clinically indicated.
Treatment activity was assessed every two cycles, accord-
ing to WHO criteria. A complete response (CR) was
defined as the disappearance of all lesions and no appear-
ance of new disease for at least 4 weeks. Partial response
(PR) was defined as a reduction by at least 50% in the sum
of the products of the two longest diameters of all lesions,
maintained for at least 4 weeks with no appearance of new
disease. CR + PR was rated as the overall response rate. Sta-
ble disease (SD) was defined as a less than 50% reduction
or less than 25% increase in the sum of the products of the
two perpendicular diameters of all measured lesions, with
no appearance of new disease. Progressive disease (PD)
was an increase of more than 25% in the size of target
lesions, or the appearance of an unequivocal new lesion.
Toxicity was evaluated according to WHO criteria after
each treatment cycle. Hematochemical assays testing
hematological, liver and renal toxicity were performed on
days 1, 6 and 15 of each cycle.
Response duration was defined as the interval between
the dates of first documented CR, or study entry in the
case of PR, and first documented sign of disease progres-
sion. TTP was measured from the dates of study entry until
disease progression or death, and survival was measured
from the dates of study entry until death from any cause.
Results
Patient characteristics
Thirty-three consecutive patients with first-line stage IIIB-
IV breast cancer from the Medical Oncology Departments
of Forlì, Rimini and Ravenna hospitals (IOR group) were
Table 1: Patient and disease characteristics at baseline
Patient characteristics Patients (n = 33)
No. %
Age 59 years
Median (range) (35–68)
PS (ECOG)
Median (range) 0 (0–1)
Menopausal status
Pre 6 18.2
Post 27 81.8
Stage
Locally advanced 7 21.2
Metastatic:
1 site 9* 27.3
≥ 1 site 17 51.5
Site
Breast 12 36.4
Bone 20 60.6
Liver 12* 36.4
Lung 8 24.2
Lymph nodes 4 12.1
Receptor status
ER+ 22 66.7
ER- 8 24.2
Unknown 3 9.1
Prior therapy
None 16 48.5
Adjuvant hormonal therapy 4 12.1
Adjuvant chemotherapy 7 21.2
Chemo- and hormone adjuvant 
therapy
41 2 . 1
Hormone therapy for advanced 
disease
61 8 . 2
*One instrumentally detected hepatic lesion was histologically 
diagnosed a posteriori as an angiomaBMC Cancer 2006, 6:76 http://www.biomedcentral.com/1471-2407/6/76
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entered onto the trial. Patient characteristics are reported
in Table 1.
Median age was 59 years (range 35 to 68 years), and the
majority of patients were postmenopausal. Median ECOG
PS was 0 (range 0 to 1). Seven patients (21.2%) had
locally advanced disease, and 17 (51.5%) had more than
one metastatic site. Bone or visceral metastases were
present in 20 (62.5%) and 19 (59.4%) patients, respec-
tively. Estrogen receptor (ER) status was positive in 22
(66.7%), negative in 8 (24.2%) and unknown in 3 (9.1%)
patients.
Sixteen patients (48.5%) had not had antiblastic therapy
of any kind, whereas 15 (46.9%) patients had received
prior adjuvant chemotherapy and/or hormone therapy,
and 6 with advanced disease had been given hormone
therapy.
Treatment activity
Of the 33 treated patients, 29 (87.8%) were assessable for
tumor response. One patient was considered ineligible
due to the absence of any measurable lesion, whereas 3
patients were not assessable for response because of treat-
ment discontinuation during the first cycle following
severe toxicity (febrile neutropenia, anaphylactic reaction
to paclitaxel and grade IV diarrhea).
Response rates for the 29 evaluable patients are shown in
Table 2. Two patients (6.9%) had a CR and 14 (48.3%)
had a PR, for an overall response rate of 55.2% (95 CI,
37.5% to 62.5%). Ten (34.5%) and 3 (10.3%) patients
showed SD and PD, respectively. The median response
duration was 16.4 months. A response was reported in all
metastatic sites and was very high in breast and lymph
node sites (75 and 100%, respectively), especially in the 7
stage IIIB patients (100%). Six of the 7 patients had a PR
after 4–8 treatment cycles and 5 of these underwent radi-
cal mastectomy. The remaining stage IIIB patient obtained
a clinical CR and, having refused radical surgery, was
treated with adjuvant radiotherapy and endocrine therapy
(letrozole). High response rates were also reported in vis-
ceral disease (69.2%), but were much lower for liver
metastases (27.3%), and none were reported for bone
lesions.
Despite preclinical data indicating a stronger synergism
and activity in ER- breast cancer cell lines, no differences
in response rates were observed between ER+ and ER-
breast cancer patients.
TTP and OS evaluation was restricted to the 26 stage IV
patients. The median TTP was 10.2 months (Figure 1A). At
a median follow-up of 31 months, 10 patients had died
and 16 were still alive, with a median OS time of 36.4
months (Figure 1B).
Treatment safety and toxicity
A total of 169 cycles were administered during the study,
with a median of 6 cycles per patient (range 1–8 cycles).
Twenty patients (62.5%) received the full number of
planned cycles, 15 received 6 cycles, and 5 received 8
cycles. One patient stopped treatment after the 5th cycle
to have radiotherapy, and two patients discontinued
chemotherapy after the 4th and 5th cycle to undergo rad-
ical surgery. Early treatment interruption was required in
five patients because of toxicity and in four patients due to
disease progression.
The planned timing of chemotherapy was respected for
most of the cycles and only 7 (4.2%) cycles were delayed.
Logistic problems caused a modest delay (16.6%) on the
6th day of treatment (gemcitabine). A dose reduction in all
three drugs was made in 23 cycles (13.6%), whereas dox-
orubicin-paclitaxel or gemcitabine dose reductions were
required in 7 (4.2%) and 9 (5.3%) cycles, respectively.
Gemcitabine was not administered in 7 cycles because of
toxicity, in 3 due to logistic problems, and in one because
of treatment interruption following disease progression
(Table 3).
All of the 33 enrolled patients were assessable for toxicity.
Toxicities observed per patient and per cycle are reported
in Table 4. As expected, the most important toxicity was
hematological. Grade 3–4 leucopenia was observed in
42% of patients and 23.6% of cycles, and grade 3–4 neu-
tropenia was recorded in 69% of patients and 48% of
cycles. Febrile neutropenia occurred in six patients
(18.1%) and nine patients (27.3%) were treated with G-
CSF, for a total of 27 cycles (16.6%). One patient died
from septic shock during the first treatment cycle, before
the first administration of gemcitabine. On the basis of
preliminary data showing high hematological toxicity, we
Table 2: Best tumor response and overall response rate (ORR) 
by disease site (n = 29)
Best tumor response No. %
Complete response 2 6.9
Partial response 14 48.3
Overall response rate 16 55.2 (CI 37.5–62.5)
No change 10 34.5
Progressive disease 3 10.3
ORR by disease site
Breast (locally advanced) 9/12 75.0
Viscera 9/13 69.2
Liver 3/11 27.3
Lymph node 6/6 100
ORR, overall response rateBMC Cancer 2006, 6:76 http://www.biomedcentral.com/1471-2407/6/76
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(A) Time to progression (TTP) and (B) overall survival (OS) Figure 1
(A) Time to progression (TTP) and (B) overall survival (OS).BMC Cancer 2006, 6:76 http://www.biomedcentral.com/1471-2407/6/76
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tested the prophylactic use of G-CSF in 5 patients (28
cycles overall): no cases of grade III-IV neutropenia were
observed and treatment was completed without delays or
significant toxicity. Grade 3 thrombocytopenia occurred
in 12% of patients and 2.4% of cycles, mild thrombocyto-
sis was observed in 34.3% of cycles, and grade 3 anemia
was recorded in 2 patients (6%). There were no cases of
grade 4 anemia or thrombocytopenia. Non hematological
toxicity was rare and mild. We observed 3 cases of grade 3
toxicity (1 nausea, 1 diarrhea, 1 stomatitis) and one case
of grade 4 diarrhea after the first treatment cycle. Neuro-
toxicity was limited (grade 1–2) and did not require treat-
ment discontinuation. There were no cases of
cardiotoxicity. Two patients experienced mild throm-
boembolism and one patient experienced an anaphylactic
reaction to paclitaxel.
Discussion
Paclitaxel has emerged as an important agent in the treat-
ment of breast cancer. The efficacy and tolerability of this
agent, as well as its lack of cross-resistance with anthracy-
clines, have led to its inclusion in combination treatments
[1]. Taxane- and anthracycline-containing regimens have
been extensively used, and one prospective phase III clin-
ical study reported a higher response rate and a longer
overall survival for paclitaxel-doxorubicin compared to 5-
fluorouracil, doxorubicin and cyclophosphamide [3].
These results, however, have been challenged by other
authors who did not demonstrate a survival advantage or
higher toxicity for taxane-based therapy [4-8]. In view of
these inconsistent results, attempts have been made to
find schedules that are capable of increasing efficacy with-
out worsening toxicity [15].
Gemcitabine has been shown to be effective and safe as a
single agent and in combination regimens and, given its
different mechanism of action and partial non cross-
resistance with anthracyclines and taxanes, represents an
ideal candidate for a three-drug regimen. Such a combina-
tion (gemcitabine, epirubicin and paclitaxel – GET) was
recently tested in a clinical setting. After very promising
results in a phase II study, with a 92% response rate [16],
the GET regimen failed to demonstrate a higher efficacy
than the FEC (5-fluorouracil, epirubicin and cyclophos-
phamide) combination in a multicenter randomized
phase III trial. In addition to the lack of a significant
advantage of GET over FEC in terms of response rate and
time to progression, the GET arm showed higher toxicity
[17].
We designed a clinical protocol based on a preclinical
schedule that had produced the highest synergistic drug
interaction in an attempt to improve the clinical efficacy
obtained with empirically designed treatment, or at least
to achieve similar results but with lower drug dosages and
milder toxicity [8,9].
In the present study, we demonstrated that the addition of
gemcitabine to doxorubicin and paclitaxel produced clin-
ical results using low doses of the three drugs, with conse-
quently minimal non hematological toxicity. In
particular, the lack of cardio- and neurotoxicity is an
important advantage because it permits anthracycline and
taxane re-treatment. Whilst it is also clear that gemcitab-
ine significantly increased myelosuppression, this toxicity
was manageable with primary or secondary G-CSF proph-
ylaxis. It is important to stress that the toxic death in our
population occurred before the first administration of
gemcitabine, i.e., after one cycle of doxorubicin and pacl-
itaxel given at lower doses than usual.
Activity data appear comparable with those reported in
the previously mentioned phase III randomized trials of
anthracycline-paclitaxel based chemotherapy in meta-
static breast cancer. In these trials [3-9], response rates
ranged from 46% to 68% and median time to progression
varied from 6 to 9.8 months. The experimentally designed
GAT regimen showed a fairly similar efficacy profile in
Table 3: Treatment compliance
n = 169 cycles
No. %
Delay 1st day
1–8 days 3 1.8
9–15 days 3 1.8
> 15 days 1 0.6
Delay 6th day
+1 11 6.5
+2 8 4.7
+3 5 3.0
> +3 4 2.4
n = 169 cycles
No. %
Dose reduction of all drugs
≤ 25% 18 10.6
26–50% 5 3.0
> 50% 0 0
Dose reduction of only A-T
≤ 25% 3 1.8
26–50% 4 2.4
> 50% 0 0
Dose reduction of only GEM
≤ 25% 2 1.2
26–50% 7 4.1
> 50% 0 0
A, doxorubicin; T, paclitaxel; GEM, gemcitabineBMC Cancer 2006, 6:76 http://www.biomedcentral.com/1471-2407/6/76
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terms of response rate and time to progression, and results
were particularly interesting for the small group of stage
IIIB patients, who all responded to treatment and the
majority of whom were operable.
Difficulties in translating in vitro results into clinical prac-
tice are inevitable. In our preclinical study [13], the syner-
gistic sequence of doxorubicin → paclitaxel →
gemcitabine was defined in two cancer cell lines, BRC-230
and MCF7, characterized by a 100% growth fraction and
a doubling time of around 30 hours. The cell kinetics of
human breast cancer are considerably different in that the
growth fraction is remarkably low and it takes several days
for the cell population to double. Moreover, we know that
in clinical practice delays may occur in drug administra-
tion due to toxicity, patient compliance, or logistic prob-
lems, and these timing violations can affect clinical
outcome. These and other important issues about transla-
tional research remain unsolved and must be addressed in
clinical research.
Conclusion
In conclusion, our results seem to indicate that the GAT
regimen is active in anthracycline-naïve metastatic breast
cancer and provides a feasible chemotherapeutic option
in this clinical setting.
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